Ignite Creation Date:
2025-12-24 @ 3:20 PM
Ignite Modification Date:
2026-01-18 @ 2:24 AM
Study NCT ID:
NCT03085992
Status:
COMPLETED
Last Update Posted:
2018-03-14
First Post:
2016-06-08
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer
Sponsor:
Azienda Ospedaliero, Universitaria Pisana
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
TRUST
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None